Rush Street Interactive Inc vs SELLAS Life Sciences Group Inc. Common Stock — how do they compare? Rush Street Interactive Inc trades at $20.26 (market cap $2.34B), while SELLAS Life Sciences Group Inc. Common Stock trades at $11.27 (market cap $2.28B). The key difference: Rush Street Interactive Inc and SELLAS Life Sciences Group Inc. Common Stock are close in size by market cap, and SELLAS Life Sciences Group Inc. Common Stock is trading nearer its 52-week high, Rush Street Interactive Inc nearer its low. Which is the better fit depends on your goals.
| RSI | SLS | |
|---|---|---|
Market Cap | $2.34B | $2.28B |
Volume | 1,702,119 | 3,128,960 |
Sector | Consumer Cyclical | Health |
52-Week High | $34.52 | $15.46 |
52-Week Low | $15.89 | $1.39 |
Typical Hold Time | 13 Days | — |
Enterprise Value | $2.01B | $2.15B |
Signals from Pluang's Aura AI — not financial advice
RSI trades at $20.24, down 1.56% amid bearish technical signals, though analyst consensus remains strongly bullish with a $34.88 price target. The company shows revenue growth to $1.13B in 2025 with expanding EBITDA margins, but faces valuation concerns with a P/E of 65.29. Recent Q2 2026 earnings beat expectations with $0.15 EPS, while institutional interest grows with BlackRock's $448M investment in August 2026.
The stock presents a growth opportunity with strong analyst support and institutional backing, but high valuation multiples and bearish technical indicators suggest near-term volatility. Execution on revenue growth and margin expansion will be critical to justify current premium pricing amid competitive online gambling market pressures.
No Aura AI signal available yet.
Trailing returns across standard periods
Rush Street Interactive, Inc. is a digital gaming and sports betting company operating in the regulated U.S. and international markets. The company owns and operates online casino (iGaming) and sports wagering platforms, including BetRivers and PlaySugarHouse brands. RSI focuses on providing a secure and high-quality online gaming experience, leveraging its proprietary technology platform and commitment to responsible gaming.
Read more on RSI →SELLAS Life Sciences is a late-stage clinical biopharmaceutical company developing therapies for cancer. Its programs include a WT1-targeting cancer immunotherapy and a selective CDK9 inhibitor.
Read more on SLS →